We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Treating Anemia With Erythropoiesis-Stimulating Agents Effects on Quality of Life

Shahriar Moossavi, MD, PhD; Barry I. Freedman, MD
Arch Intern Med. 2009;169(12):1100-1101. doi:10.1001/archinternmed.2009.159.
Text Size: A A A
Published online


Isolation and cloning of the human erythropoietin gene resulted in injectable forms of erythropoiesis-stimulating agents (ESAs) suitable for pharmacological use. This breakthrough transformed the lives of millions of individuals with chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide. The severity and prevalence of anemia are closely associated with kidney dysfunction; the frequency of anemia increases from 27% to 76% with a decline in glomerular filtration rate1 from more than 60 mL/min/1.73 m2 to less than 15 mL/min/1.73 m2. Prior to ESAs, dialysis-associated anemia was typically treated with regular blood transfusions and anabolic steroids.2 Iron overload commonly resulted, and treated patients often had hemoglobin (Hb) concentrations lower than 10 g/dL (to convert to grams per liter, multiply by 10.0). Erythropoiesis-stimulating agents currently available in the United States include epoetin alfa and darbepoetin alfa, and their differential carbohydrate content determines plasma half-life and dosing interval.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

3 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles

Care at the Close of Life: Evidence and Experience
Anemia Contributing to Fatigue

Care at the Close of Life: Evidence and Experience
Treatment of Anemia